The almost yearly Access to Medicine Index measures the 20 behemoths of the pharmaceutical industry, encapsulating 70% of global pharmaceutical revenues.
However, the report doesn't look at the bottom line: It looks at medicine accessibility in low- and middle-income companies (LMICs), and—as with everything in the past year—COVID-19 made its mark, demanding supply chain innovation and collaboration in new ways.In a foreword to the report, Access to Medicine Foundation Executive Director Jayasree K.
Iyer writes, "The Access to Medicine Index provides a guide to the practical, proven steps that can be taken by multinational pharmaceutical companies to improve access to life-saving medicines.